S2-E35 – #ILC2021 Day Four – Promising Times Ahead, Maybe With a Few More Bumps In the Road

Donna Cryer, Vlad Ratziu, Michael Charlton and Mazen Noureddin join Roger Green in reviewing the final day of #ILC 2021.

The conversation revolved around three themes: non-invasive tests as presented at the morning LITMUS session; two promising but incomplete drug trials for a new class of agents and a possible therapy for controlled cirrhotics, and the opportunities and challenges presented by digital meetings (with kudos to EASL for all the platform elements they strengthened from 2020.

TOPICS: AASLD, Akero Therapeutics, aldafermin, cirrhosis, EASL, EchoSens, efruxifermin, ELF, Fatty Liver, FGF-21, FIB-4, FibroScan, Fibrosis Level 3, Fibrosis Level 4, Gilead Sciences, Global Liver Institute, inventiva, lanifibranor, MRI-PDFF, NAFLD, NASH, Nordic Biosciences, Patient Advocacy, Phase3, population screening, Semaglutide, social policy, North Sea Therapeutics, icosabutate, ICONA trial, FAST test, MRE, food insecurity, Pro-C3

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"